The Patent Finder

Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan

Ipsen Biopharm Ltd.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 8 of these applications claim priority to application PCT/US2013/045495, filed Jun 12, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,339,497Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · High confidence
Ipsen Biopharm Ltd.In force
High confidence
US 9,364,473Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · Medium confidence
Ipsen Biopharm Ltd.In force
Medium confidence
US 9,452,162Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · Medium confidence
Ipsen Biopharm Ltd.In force
Medium confidence
US 9,492,442Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · Medium confidence
Ipsen Biopharm Ltd.In force
Medium confidence
US 9,717,724Methods for Treating Pancreatic Cancer Using Combination Therapies
In force
 · Low confidence
Ipsen Biopharm Ltd.In force
Low confidence
US 10,980,795Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
In force
 · Medium confidence
Ipsen Biopharm Ltd.In force
Medium confidence
US 11,369,597Methods For Treating Pancreatic Cancer Using Combination Therapies
In force
 · Low confidence
Ipsen Biopharm Ltd.In force
Low confidence
US 12,364,691Methods For Treating Pancreatic Cancer Using Combination Therapies
In force
 · Low confidence
Ipsen Biopharm Ltd.In force
Low confidence
Application 15/059,640Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Abandoned
Abandoned Jul 5, 2017
Ipsen Biopharm Ltd.AbandonedAbandoned Jul 5, 2017
Application 15/341,377Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Abandoned
Abandoned Nov 27, 2017
Ipsen Biopharm Ltd.AbandonedAbandoned Nov 27, 2017
8 more patents in this group · Pro
10 of 18 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 18.
Upgrade to Pro
8 of these are in force and held by Ipsen Biopharm Ltd..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited